UNASSIGNED: A randomized, controlled, double-blind, multicenter clinical trial, in which a new immunomodulatory formula with extra virgin olive oil was compared with a standard isoprotein and isoenergetic formula. Patients with gastric, esophageal or biliopancreatic tumors were recruited to receive two units of immunomodulatory formula or control, 5 days before the surgical intervention.
UNASSIGNED: A total of 119 patients were recruited. There was a significant reduction in the number of reinterventions (7.7 vs. 20.4%; p = 0.044) in the intervention group. There was a significant reduction in the development of fistulas in patients with phase angles >5.7°. Also, there were fewer readmissions after biliopancreatic surgeries (0.0 vs. 100%; p = 0.014). The length of hospital stay was similar between groups; however, with the immunomodulatory formula, the patients exhibited greater phase angle at the end of follow-up.
UNASSIGNED: The immunomodulatory formula with extra virgin olive oil administered 5 days before surgery for stomach, esophageal and biliopancreatic tumors improved cellular health and reduced postoperative complications.Clinical trial registration: [https://clinicaltrials.gov/], identifier [NCT04027088].
■随机,控制,双盲,多中心临床试验,其中将特级初榨橄榄油的新免疫调节配方与标准的同工酶和等能量配方进行了比较。胃病患者,食管或胆胰腺肿瘤被招募接受两个单位的免疫调节配方或对照,手术干预前5天。
■共纳入119名患者。重新干预的数量显着减少(7.7vs.干预组为20.4%;p=0.044)。相位角>5.7°的患者瘘管的发展明显减少。此外,胆胰手术后的再入院率较低(0.0vs.100%;p=0.014)。两组之间的住院时间相似;然而,用免疫调节配方,患者在随访结束时表现出更大的相位角.
■在胃手术前5天给予特级初榨橄榄油的免疫调节配方,食管和胆胰肿瘤改善了细胞健康,减少了术后并发症。临床试验注册:[https://clinicaltrials.gov/],标识符[NCT04027088]。